Pathogenesis and progression of monoclonal gammopathy of undetermined significance

被引:66
|
作者
Blade, J. [1 ]
Rosinol, L. [1 ]
Cibeira, M. T. [1 ]
de Larrea, C. F. [1 ]
机构
[1] Univ Barcelona, Dept Hematol, Inst Hematol & Oncol, IDIBAPS,Hosp Clin, Barcelona, Spain
关键词
monoclonal gammopathy of undetermined significance; smouldering multiple myeloma; malignant transformation;
D O I
10.1038/leu.2008.203
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In Caucasians, monoclonal gammopathy of undetermined significance (MGUS) is an age-related condition with prevalence as high as 3% in persons older than 50 years. Compared with whites, blacks have around two-and threefold higher prevalence rates of MGUS and multiple myeloma (MM), respectively. Risk of progression from MGUS to MM has been found to be very similar in whites and blacks. On average, the transformation rate to a malignant monoclonal gammopathy is 1% per year, with the mechanisms of progression likely related to bone marrow microenvironment and/or the cytokine network. Overall, the actuarial probability of progression at 25 years of follow-up is about 30%. However, when the competing causes of death are taken into account, the actual rate of progression is only 11%. The predictors of malignant transformation are the plasma cell mass (M-protein size and/or proportion of plasma cell in the bone marrow), IgA isotype, serum free light-chain ratio and 'evolving' type and ratio between phenotypically aberrant and normal bone marrow plasma cells. It is recommended to follow these patients, particularly those with high risk of progression, annually to detect MM before complications, such as renal failure or extensive skeletal, involvement occur.
引用
收藏
页码:1651 / 1657
页数:7
相关论文
共 50 条
  • [21] What is the significance of monoclonal gammopathy of undetermined significance?
    Atkin, Catherine
    Richter, Alex
    Sapey, Elizabeth
    CLINICAL MEDICINE, 2018, 18 (05) : 391 - 396
  • [22] Curcumin for the prevention of progression in monoclonal gammopathy of undetermined significance: A word of caution
    Vermorken, A. J. M.
    Zhu, J.
    Van de Ven, W. J. M.
    Cui, Y.
    Fryns, J. P.
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2010, 1 (02) : 265 - 269
  • [23] Identification of the potential risk factors for monoclonal gammopathy of undetermined significance of progression
    Li, Rong
    Du, Juan
    Hou, Jian
    HEMATOLOGY, 2015, 20 (01) : 11 - 17
  • [24] MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE AND NEUROPATHY
    Ui, J. C.
    Tavee, J. O.
    MUSCLE & NERVE, 2009, 40 (04) : 694 - 694
  • [25] Monoclonal gammopathy of undetermined significance (MGUS)
    Kyle, RA
    BAILLIERES CLINICAL HAEMATOLOGY, 1995, 8 (04): : 761 - 781
  • [26] In the Clinic Monoclonal Gammopathy of Undetermined Significance
    Gonsalves, Wilson I.
    Rajkumar, S. Vincent
    ANNALS OF INTERNAL MEDICINE, 2022, 175 (12) : ITC177 - ITC192
  • [27] Prevalence of monoclonal gammopathy of undetermined significance
    Kyle, RA
    Therneau, TM
    Rajkumar, SV
    Larson, DR
    Plevak, MF
    Offord, JR
    Dispenzieri, A
    Katzmann, JA
    Melton, LJ
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (13): : 1362 - 1369
  • [28] Monoclonal gammopathy of undetermined significance - Reply
    Kyle, RA
    Rajkumar, SV
    Melton, J
    NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (26): : 2088 - 2088
  • [29] IgD monoclonal gammopathy of undetermined significance
    Kinoshita, T
    Nagai, H
    Murate, T
    Saito, H
    Fukatsu, T
    Hotta, T
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 1997, 65 (02) : 169 - 172
  • [30] Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detection
    Visram, Alissa
    Larson, Dirk
    Norman, Aaron
    Dispenzieri, Angela
    Murray, David
    Kyle, Robert
    Rajkumar, S. Vincent
    Slager, Susan
    Kumar, Shaji
    Vachon, Celine
    BLOOD, 2025, 145 (03) : 325 - 333